130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
2 citations
,
June 2023 in “Current Nutrition & Food Science” Hinokiflavone may help treat cancers and other health issues.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
4 citations
,
March 2012 in “Annals of oncology” New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
9 citations
,
May 2013 in “JAMA Dermatology” A woman's hair turned white after taking a cancer drug called dasatinib.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” Cepharanthine may help treat lung fibrosis by affecting certain immune cells.
June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
19 citations
,
August 2023 in “Journal of Dermatological Treatment” Abrocitinib may effectively treat stubborn alopecia universalis.
12 citations
,
March 2021 in “JAAD Case Reports” Nail changes from immunotherapy can be managed without stopping cancer treatment.
22 citations
,
September 2017 in “Skin appendage disorders” Ruxolitinib helped a man regrow his beard after years of hair loss.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
1 citations
,
December 2020 in “Case reports in dermatological medicine” A patient with pemphigus vulgaris improved significantly after treatment for an additional viral skin infection.
16 citations
,
July 2020 in “International Journal of Molecular Sciences” Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
March 2026 in “Journal of Translational Autoimmunity” Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
1 citations
,
March 2023 in “Journal of the American College of Cardiology” 2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
February 2014 in “Cancer Research” Recent findings advanced understanding of cancer mechanisms and potential treatments.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.